News and Events, Recent News

BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®

· Patient dosing is underway in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) or YERVOY® (by Bristol-Myers Squibb Company) in advanced breast cancer. · KEYTRUDA® and YERVOY® have been highly recognized for their potent immune boosting properties – Nobel Prize in Medicine 2018 – validating BriaCell’s strategy to use these […]

News and Events, Recent News

BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study

· BriaCell has achieved positive proof of concept in the Phase IIa study of Bria-IMT™ in advanced breast cancer patients · Data shows promising anti-tumor activity of Bria-IMT™ in heavily pre-treated advanced breast cancer patients · Impressive Phase IIa efficacy data is similar or superior to those of other approved breast cancer drugs of similar […]

News and Events, Recent Events

BriaCell Therapeutics Corp. Discusses its Plan to Revolutionize Cancer Immunotherapy in Exclusive NetworkNewsWire Audio Interview

NEW YORK (Sept 25, 2018) – via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) (“BriaCell” or “the Company”), focused on developing a targeted and safe […]

News and Events, Recent Events

Coverage Initiated for BriaCell Therapeutics Corp. via NetworkNewsWire

NEW YORK, Sept. 21, 2018 (GLOBE NEWSWIRE) — via NetworkWire – BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V) (BriaCell or the Company), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announces that it has selected NetworkNewsWire (“NNW”) to assist the Company with its corporate communications initiatives. BriaCell is currently developing a targeted […]

News and Events, Recent News

BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences

– Scientific findings will discuss circulating tumor cells as a biomarker of tumor response, which is key to the advancement of BriaCell’s BriaDX™, a diagnostic test designed to determine which patients are most likely to respond to treatment. – Phase I/IIa clinical efficacy data will be announced in advance of these conferences. (Accesswire — September […]

News and Events, Recent Events

Dr. William Williams, BriaCell’s President & CEO, is Featured in an Exclusive New Audio Interview at SmallCapVoice.com

AUSTIN, Texas—8/28/18– SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. (“BriaCell”) (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President & CEO, Dr. William Williams, is featured in a new audio interview at SmallCapVoice.com, Inc. The new Bricell interview can be heard at https://smallcapvoice.com/blog/8-27-18-smallcapvoice-interview-with-briacell-therapeutics-corp-bctxf/. Dr. Williams, BriaCell’s […]

News and Events, Recent News

BriaCell Adds New Clinical Site To Phase IIa Study in Advanced Breast Cancer and Expands R&D Team

• The addition of the Cancer Center of Kansas (CCK) as a new clinical trial site is expected to accelerate patient enrollment in both clinical trials. • The hiring of Dr. Sunkari, an experienced Scientist, is intended to speed up the development of Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy. BERKELEY, Calif. and VANCOUVER, British Columbia, […]

News and Events, Recent News

BriaCell to Hold Conference Call on Key Clinical Findings; Activities

BERKELEY, Calif. and VANCOUVER, British Columbia, June 21, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to provide a Corporate Update on its activities and new developments, including positive Phase IIa safety information, discovery of tumor shrinkage mechanism, and patient […]